Fresenius Group, Germany is one of Global Fortune 500 companies which provides products for dialysis and infusion. Its wholly-owned subsidiary, Beijing Fresenius Kabi, launches the phase-II project in Beijing, which has laid the foundation in the Daxing Biomedicine Industry Base. This project will improve the supply chain system of this international pharmaceutical giant in China.

Fresenius Group, Germany is a medical company offering products for dialysis, infusion and clinical nutrition treatment, hospital and home medical care as well as supporting services. It was founded in 1912 with its headquarters located in Bad Homburg, Germany, and has been ranked among the world's top 500 industry leading position for many years. Beijing Fresenius Kabi Pharmaceutical Co., Ltd. established in 1994 is a wholly-owned subsidiary of Fresenius Group in China.

The Fresenius kabi Project is accelerating the overall layout and development of Beijing, and the cooperation exchange has been carried out with respect to medical insurance, consulting, generic drugs, pharmaceutical import, configuration outsourcing and other aspects, and the schemes for pharmaceutical configuration outsourcing service and the cooperation schemes for health management, medical insurance cooperation, commercial insurance projects and other aspects have been pushed forwarded.

Beijing Fresenius Kabi Project in Daxing Biomedicine Industry Base covers an area of 66 mu with a total investment of about CNY0.5 billion. Since Fresenius Group decided to invest in building a plant in the pharmaceutical base in early 2013, under the strong support and care of Beijing Municipal Government, Daxing District Government, Daxing Biomedicine Industry Base and the authorities concerned, the project has been completed on schedule and achieved full production and operation with reaching target output in 2017. For Beijing Fresenius kabi Pharmaceutical Co., Ltd., it has achieved the sales volume of CNY2.32 billion and the tax revenue of CNY392 million in 2018, and its annual value of production was expected to be CNY2.7 billion in 2019. This pharmaceutical preparation plant is a larger fixed-asset investment project of Fresenius Group in China in recent years, and is also a solely-invested production plant built by Fresenius Group in China for the first time, which shows the firm belief of Fresenius Group on being rooted in Beijing and serving China.